NCT02365727

Brief Summary

Patients will be randomized (like the flip of a coin) to receive Exparel and a nerve block, standard of care for this procedure, or Exparel alone for pain management after surgery. They will also be asked to complete questionnaires before surgery, during their stay at the hospital after surgery, then at 3 months, 6 months and 12 months after surgery to assess pain and/or function levels, as well as the amount of pain medicine patients have used after surgery. Patients' leg strength will be measured immediately after surgery and again at 3, 6 and 12 months after surgery.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2015

Shorter than P25 for phase_4 knee-osteoarthritis

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 11, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 19, 2015

Completed
1 month until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
Last Updated

January 14, 2016

Status Verified

January 1, 2016

Enrollment Period

4 months

First QC Date

February 11, 2015

Last Update Submit

January 13, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain as assessed by Visual Analog Scale (VAS)

    Pain, as assessed by Visual Analog Scale (VAS)

    12 Months

Secondary Outcomes (2)

  • Function as assessed by Knee Society Score (KSS) and EQ-5D

    12 Months

  • Opioid consumption as assessed by dosage and frequency of narcotic usage

    30 hours

Study Arms (2)

Exparel plus Adductor Canal Block

EXPERIMENTAL

Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine

Drug: Liposomal bupivacaineDrug: RopivacaineDrug: EpinephrineDrug: Clonidine

Exparel plus Placebo Block

PLACEBO COMPARATOR

Adductor canal block with 20 cc saline

Drug: Liposomal bupivacaineDrug: Saline

Interventions

Also known as: Exparel
Exparel plus Adductor Canal BlockExparel plus Placebo Block
Exparel plus Adductor Canal Block
Exparel plus Adductor Canal Block
Exparel plus Adductor Canal Block
SalineDRUG
Exparel plus Placebo Block

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female, aged 18 to 80 years at the time of surgery.
  • Willing and able to give voluntary informed consent to participate in this investigation.
  • Candidate for total knee arthroplasty.
  • BMI \< 35.

You may not qualify if:

  • Subject has had previous arthroplasty or fracture procedure(s) on the operative knee.
  • Creatine level ≥ 1.5
  • Pre-existing gait disturbance or neuropathy.
  • Allergy to local anesthetics.
  • Inflammatory arthropathies.
  • Female patient who is pregnant or nursing.
  • Chronic use of narcotics
  • Any other reason (in the judgment of the investigator).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Steadman Hawkins Clinic of the Carolinas - Greenville Health System

Greenville, South Carolina, 29615, United States

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

RopivacaineEpinephrineClonidineSodium Chloride

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesEthanolaminesAmino AlcoholsAlcoholsBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsImidazolinesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Brayton Shirley

    Steadman Hawkins Clinic of the Carolinas - Greenville Health System

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 11, 2015

First Posted

February 19, 2015

Study Start

April 1, 2015

Primary Completion

August 1, 2015

Study Completion

August 1, 2015

Last Updated

January 14, 2016

Record last verified: 2016-01

Locations